FDA Workforce Reduction Impact on Medical Device Regulatory Timelines: What Manufacturers Need to Know in 2026

The FDA Staffing Crisis: By the Numbers

Since September 2024, the FDA has lost approximately 21% of its workforce -- more than 4,400 people. The Center for Devices and Radiological Health (CDRH), which oversees medical device review and regulation, has been hit particularly hard: approximately 22% of its workforce has been eliminated, reducing the center from roughly 2,260 reviewers and inspectors to an estimated 1,800.

These are not theoretical concerns. The cuts have produced measurable operational consequences for every medical device company that interacts with the FDA -- which is to say, every medical device company marketing products in the United States.

This article examines what has actually happened to FDA device review operations, separates documented impacts from industry speculation, and provides actionable strategies for manufacturers navigating a regulatory system under significant staffing strain.

Timeline of FDA Workforce Changes

The reductions did not happen all at once. They unfolded across multiple rounds, each compounding the operational impact:

The April 2025 HHS cuts were the most consequential single event. Employees were placed on administrative leave with formal separation dates in June 2025, giving CDRH limited time to redistribute workloads. The subsequent partial restoration of mission-critical roles helped preserve core review functions but did not fully replace lost capacity in policy development, guidance document updates, or specialized review areas.

What Is Actually Happening vs. What FDA Says

There is a growing gap between the FDA's official posture and the ground-level experience reported by device manufacturers and regulatory consultants.

The Official Position

CDRH leadership has maintained that the center is meeting its MDUFA V review timeline commitments. CDRH Director Dr. Michelle Tarver stated that 2025 "brought several changes that required us to adjust our pace and focus our efforts," but emphasized that statutory review clocks continue to be met.

This is technically accurate. The MDUFA V performance commitments measure whether the FDA meets specific review milestones within defined timeframes -- things like the 90-day target for 510(k) decisions or the 180-day target for De Novo classifications. By those metrics, CDRH is largely on track.

The Ground-Level Reality

The problem is that statutory clock compliance does not capture the full picture. What manufacturers are experiencing goes beyond what MDUFA metrics measure:

Slower email responses. FDA reviewers who previously responded to informal inquiries within days are now taking weeks. Interactive review correspondence -- the back-and-forth that resolves issues during active review -- has slowed noticeably.

Delayed meeting scheduling. Pre-Submission meeting timelines have stretched significantly. The most stark example: Kezar Life Sciences requested a Type C meeting in early 2025. It was scheduled for October 2025, then cancelled by FDA without explanation, and rescheduled for February 2026. By the time FDA signed off, Kezar had already cut 70% of its workforce and was winding down operations. The asset was ultimately picked up by Aurinia Pharmaceuticals, but Kezar no longer exists as an independent company. While Kezar's situation involved multiple factors beyond FDA delays, the meeting timeline contributed to the company's inability to maintain operations during a critical period.

Reviewer churn. Companies are reporting that reviewers are leaving mid-cycle, forcing a complete restart of the regulatory dialogue. In one documented case involving a Software as a Medical Device (SaMD) Class IIb submission, a senior reviewer was assigned in January 2026, left the agency in March 2026, and a new reviewer was assigned in April 2026 -- producing a four-month slip in actual time-to-clearance, even though the statutory clock was still running throughout.

Inconsistent feedback on novel technologies. With fewer experienced reviewers, particularly in specialized areas, companies are receiving less predictable feedback. Multiple reviewers may weigh in with differing perspectives, and the departure of a subject matter expert can shift the agency's position between the Pre-Submission and formal submission stages.

Reduced policy output. CDRH issued fewer guidance documents and policy statements in 2025 than in prior years, despite receiving more submissions. Fewer updated guidances means more regulatory uncertainty for manufacturers, particularly in emerging technology areas.

Barb Marsden, Acting Director of the Office of Regulatory Programs (ORP) within the Office of Product Evaluation and Quality (OPEQ), acknowledged the situation directly at the FDA's MedCon conference on April 22, 2026: "We are seeing signs of strain... We're running out of bandwidth to get all our work done."

The Numbers: CDRH Capacity and Throughput

Understanding the operational impact requires looking at both capacity and demand:

The demand-supply mismatch is clear: CDRH is processing more submissions with substantially fewer staff. The center has maintained throughput volume, but the mechanisms for doing so -- heavier workloads per reviewer, reduced time for non-clock activities like guidance development and informal correspondence -- have produced the operational friction manufacturers are experiencing.

510(k) Review Times

Traditional 510(k) clearance times remain in the range of 140-175 calendar days, with 70-80% of submissions exceeding the 90-day MDUFA target. Median clearance time in early 2026 actually appears slightly improved on paper compared to 2024, which CDRH has cited as evidence that the review process remains functional.

However, regulatory consultants note that this metric captures only the formal review period. The total time from initial submission to clearance -- including time spent responding to Additional Information requests, resubmitting after refusals to accept, and navigating reviewer reassignments -- has lengthened for many companies.

Breakthrough Device Designation Backlog

As of December 2025, the FDA had granted 1,246 Breakthrough Device Designations (BDDs) since the program's inception. Only 185 of those designated devices had received marketing authorization. While not all designated devices are ready for submission, the growing gap between designation and authorization suggests that even the priority review track is experiencing capacity constraints.

Mixed Evidence: Why the Picture Is Complicated

The impact of workforce reductions is not uniform across all submission types, companies, or review divisions. The evidence is genuinely mixed:

Some consultants report no significant delays. Several experienced regulatory affairs professionals have noted that their active 510(k) projects are proceeding on timelines comparable to pre-2025 norms. This may reflect variation between CDRH review divisions, with some divisions retaining more staff than others.

Other reports describe applications "idling." Some companies report that their submissions receive initial acknowledgment but then experience extended periods with no reviewer contact or activity, only to receive a burst of questions near the end of the statutory review period.

The full impact may still be developing. Many of the most significant staffing losses occurred in mid-2025. The remaining staff has been absorbing increased workloads, and there are limits to how long that is sustainable without degradation in quality or timeliness. The full effect on review operations may not be apparent until late 2026 or beyond.

CDRH is adapting. The FDA has begun tracking interactive review responses to improve transparency, and the agency is exploring the use of AI tools to assist review processes. Marsden noted at MedCon 2026: "We're learning how to use AI in the most appropriate ways possible."

What is clear is that the system is under strain, even if it has not broken. Companies that plan their regulatory timelines assuming best-case scenarios are taking on unnecessary risk.

Disproportionate Impact on Small Companies and Startups

Large medical device manufacturers have in-house regulatory teams, established relationships with FDA review staff, and the financial reserves to absorb timeline shifts. For these companies, a three-to-six-month delay in a 510(k) clearance is a frustration that affects launch planning but does not threaten survival.

For startups and small companies, the calculus is fundamentally different:

• Cash burn during delays. A startup running a clinical program or maintaining a regulatory affairs team while waiting for FDA clearance is burning cash with no revenue to offset it. A six-month delay can represent millions of dollars in additional burn.
• Limited parallel strategy options. Large companies can pursue FDA, EU MDR, and other market access strategies concurrently. Startups typically focus on one market first -- usually the US -- and a delay in that primary pathway can cascade into delays across the entire commercialization plan.
• Investor confidence. Timeline extensions erode investor confidence, particularly for companies that have already experienced regulatory setbacks. The Kezar Life Sciences example illustrates how regulatory delays can contribute to a death spiral for a small company.
• Reduced leverage in FDA interactions. Smaller companies typically have less experience navigating FDA review and fewer internal resources to devote to rapid response when reviewers send questions or request additional information. When reviewer churn introduces new contacts and potentially new expectations, small companies are less equipped to adapt.

Impact by Submission Type

The effects of CDRH workforce reductions vary significantly depending on the type of submission:

510(k) Submissions

Statutory timelines are being met, but actual clearance times may extend 3-6 months beyond what companies have historically experienced, primarily due to reviewer churn and slower interactive review correspondence. The 90-day MDUFA target remains the benchmark, but 70-80% of submissions continue to exceed it. With fewer reviewers, the frequency and quality of mid-review interactions has declined.

Key risk: Reviewer reassignment mid-cycle, requiring re-education of the incoming reviewer on device-specific issues.

Premarket Approval (PMA)

PMA reviews require higher scrutiny and involve more specialized expertise. The pool of experienced reviewers for complex devices -- particularly those involving novel materials, combination products, or advanced surgical techniques -- was already thin. Workforce reductions have made it thinner. PMA applicants should expect less interactive engagement during the review and potentially more conservative review outcomes as remaining reviewers manage heavier portfolios.

Key risk: Fewer experienced reviewers available for panel-track devices and high-complexity PMAs.

De Novo Classification

The De Novo pathway, which establishes new device classifications, requires reviewers to make novel classification decisions. This pathway has always been resource-intensive, and the reviewer pool was small to begin with. With workforce reductions, De Novo review times have become less predictable. Companies pursuing De Novo should budget additional time and invest heavily in Pre-Submissions to establish reviewer alignment before formal submission.

Key risk: New pathway reviewers are thin, especially for novel technologies where no direct precedent exists.

Pre-Submissions (Q-Submissions)

Pre-Submission meeting scheduling has been one of the most visibly affected areas. Multiple companies have reported significant delays in getting meetings scheduled, cancellations without explanation, and inconsistent feedback quality when meetings do occur. This is particularly problematic because Pre-Submissions are the primary mechanism for de-risking formal submissions. When companies cannot get timely feedback, they may proceed to formal submission with unresolved questions, increasing the risk of Additional Information letters and review delays.

Key risk: Meeting scheduling delays and inconsistent feedback quality undermine the de-risking function of the Pre-Submission program.

Breakthrough Device Designation

The BDD program is showing signs of strain. With 1,246 designations granted and only 185 resulting in marketing authorization, the program has a substantial pipeline of designated devices progressing toward submission. The priority review benefits of BDD -- sprint discussions, senior management involvement, and accelerated scheduling -- depend on FDA staff availability. When staff are stretched thin, even priority reviews slow down.

Key risk: Growing backlog with insufficient specialized review capacity to maintain the program's intended pace.

AI/ML and Software as a Medical Device (SaMD)

CDRH has authorized more than 1,250 AI-enabled devices to date, but the specialist reviewer pool for AI/ML technologies has been approximately halved by workforce reductions. AI/ML reviews require expertise in algorithm validation, clinical study design for adaptive technologies, predetermined change control plans, and software lifecycle processes. This is not a skill set that can be quickly replaced.

First-of-kind AI/ML device submissions face particular risk, as the remaining reviewers are managing significantly larger portfolios and have less bandwidth for novel technology evaluation.

Key risk: Specialist reviewer pool halved, with no rapid path to rebuilding this expertise.

Investigational Device Exemptions (IDE)

IDE reviews, which authorize clinical investigations of devices, are essential for companies conducting US-based clinical trials. Delayed IDE approvals can push back clinical trial start dates, affecting enrollment timelines, data generation milestones, and ultimately the timeline for market authorization. Companies should submit IDE applications as early as feasible and use Pre-Submissions to align on study design before formal IDE submission.

Key risk: IDE review delays cascade into clinical trial timeline delays and downstream regulatory milestones.

MDUFA VI Negotiations: What Is Ahead

The current MDUFA V agreement runs through FY2027. Negotiations for MDUFA VI -- the next five-year user fee agreement covering FY2028 through FY2032 -- are already underway. These negotiations between FDA and industry stakeholders will determine review performance goals, user fee levels, and resource commitments for the next half-decade.

Several issues are likely to be central to MDUFA VI discussions:

• Staffing and resource adequacy. Industry will push for commitments around reviewer staffing levels, training, and retention. The workforce reductions of 2024-2026 have eroded industry confidence in the agency's ability to maintain review capacity.
• Review timeline metrics. The current MDUFA metrics focus on statutory clock compliance. Industry may advocate for additional metrics that capture the full submission-to-clearance timeline, including interactive review periods and reviewer reassignment impacts.
• Guidance document commitments. The decline in guidance document output is creating regulatory uncertainty. MDUFA VI may include specific commitments on guidance development timelines for emerging technology areas.
• Technology and process modernization. FDA's exploration of AI-assisted review tools may feature in MDUFA VI as both a resource investment and a potential mechanism for maintaining review throughput with reduced staffing.

The outcome of MDUFA VI negotiations will shape the FDA device review landscape through at least 2032. Companies should monitor these negotiations closely, as the resulting commitments will directly affect regulatory planning assumptions.

Practical Mitigation Strategies for Device Manufacturers

Regulatory strategy must now account for FDA operational constraints as a variable, not a constant. The following strategies are designed to reduce risk and improve outcomes in the current environment.

Strategy 1: Tighter Pre-Submission Packages

Invest more resources in Pre-Submission preparation. A well-crafted Pre-Submission that generates clear FDA alignment before formal submission is more valuable now than it has been in years.

• Submit highly focused questions -- limit each Pre-Submission to three to five specific, clearly defined topics. This makes it easier for reviewers to provide substantive responses even under time pressure.
• Include proposed study designs, acceptance criteria, and testing protocols rather than open-ended questions. Give reviewers something concrete to react to.
• Use the Pre-Submission to establish agreement on the regulatory pathway, predicate device selection (for 510(k)), and clinical evidence requirements. Resolving these questions upfront reduces the risk of mid-review surprises.
• Follow up promptly on FDA feedback. If feedback is unclear or inconsistent, request clarification immediately rather than waiting until the formal submission.

For detailed guidance on preparing effective Pre-Submissions, see our FDA Pre-Submission (Q-Submission) Guide.

Strategy 2: Build Buffer Time into Project Plans

If your financial model or investor commitments assume 510(k) clearance in six months, add three to six months of buffer for reviewer churn and interactive review delays. For AI/ML features, expect first-of-kind scrutiny from a team that has lost roughly half its specialists.

• Update project timelines to reflect realistic review durations: 510(k) in 6-9 months (rather than 3-6), De Novo in 12-18 months (rather than 9-12), and PMA in 18-24 months (rather than 12-18).
• Build decision points into your timeline. For example: "If no substantive FDA contact by Day 60, escalate through the Division Director."
• Communicate realistic timelines to investors, board members, and commercial teams early. Managing expectations now prevents confidence erosion later.

Strategy 3: Pursue Parallel Regulatory Strategies

Do not wait for FDA clearance to begin regulatory work in other markets. Concurrent submissions to the EU (MDR), UK (UKCA/MUKLS), and other jurisdictions can provide market access alternatives if FDA timelines slip.

• Begin EU MDR conformity assessment early, particularly if your device requires notified body involvement. EU notified body timelines are long but at least predictable. See our EU MDR Notified Body Guide.
• Consider markets with faster regulatory pathways -- Australia TGA, Health Canada, and Singapore HSA all offer pathways that may be faster than the current FDA timeline for your device.
• For AI/ML devices, the EU AI Act introduces additional requirements but also provides a structured framework. Understanding EU requirements early can inform your FDA strategy as well.

Strategy 4: Proactive Communication with FDA

Interactive review is becoming a more formalized process, and FDA is now tracking interactive review responses. Use this to your advantage.

• Submit concise, well-organized responses to FDA questions. Avoid voluminous packages that overwhelm already-stretched reviewers.
• Request meetings early and be flexible with scheduling. If FDA proposes a meeting date that is later than ideal, accept it rather than pushing for an earlier date that may be cancelled and rescheduled even later.
• Use the Submission Issue Request (SIR) mechanism when your submission is on hold. A SIR can help clarify FDA expectations before you invest time in a formal response.
• Document all FDA interactions carefully. If reviewer churn occurs, having a clear record of prior agreements and feedback makes it easier to bring a new reviewer up to speed.

Strategy 5: Regulatory Intelligence and Monitoring

With fewer FDA guidance documents being issued, regulatory intelligence becomes more important -- and more difficult.

• Monitor FDA guidance updates closely. When new guidances are issued, they may represent shifts in agency thinking that have been developing for months or years without public documentation. See our FDA 510(k) Database Guide for tools to track recent submissions and clearances.
• Track clearance trends for devices similar to yours. If review times for your device type are lengthening, adjust your timeline accordingly.
• Engage with industry associations (AdvaMed, MDMA, RAPS) that have direct communication channels with CDRH leadership. Association briefings often provide earlier insight into operational changes than official FDA communications.
• Review advisory panel meeting transcripts and presentations (such as MedCon) for candid assessments of CDRH operational status.

Strategy 6: Internal Readiness

Prepare your organization for the operational realities of the current environment.

• QMSR readiness. With potentially reduced FDA inspection capacity, ensure your quality management system is fully aligned with the new Quality Management System Regulation. Inspections may be less frequent but potentially more focused. See our QSR to QMSR Transition Guide.
• Cybersecurity documentation. Section 524B cybersecurity requirements are now a top hold reason for device submissions. Have a complete Software Bill of Materials (SBOM), threat model, and cybersecurity management plan ready before submission. Incomplete cybersecurity packages will result in Additional Information letters that add weeks or months to the review timeline.
• Reviewer reassignment contingency. Prepare a concise "reviewer handoff package" that summarizes key decisions, agreements from Pre-Submissions, and the regulatory history of your device. If your reviewer changes mid-cycle, having this package ready can accelerate the transition.
• Internal regulatory capacity. If your team is lean, consider engaging external regulatory consultants for surge capacity during active review periods. The cost of consultant support is modest compared to the cost of a six-month timeline slip.

Impact Assessment Summary Table

The following table summarizes the expected impact of FDA workforce reductions by submission type, based on available data and industry reports as of May 2026:

Looking Ahead: What to Expect Through 2026-2027

Several factors will determine whether FDA device review operations improve, stabilize, or further degrade over the next 12-18 months:

Staffing recovery. FDA has indicated it is working to return to planned staffing levels during the remainder of MDUFA V. The speed and completeness of this rebuilding effort will depend on federal budget decisions, hiring pipeline constraints, and the agency's ability to attract and retain specialized talent in a competitive labor market. Rebuilding AI/ML expertise, in particular, requires recruiting professionals with deep technical skills who could command higher compensation in the private sector.

Contract resources. CDRH is using contract reviewers and external resources where appropriate to supplement internal capacity. This can help with routine reviews but is less effective for novel technology evaluation, policy development, and complex decision-making that requires deep institutional knowledge.

AI-assisted review. The FDA's exploration of AI tools for review support is still in early stages. While promising, AI-assisted review is unlikely to replace the judgment of experienced reviewers for complex submissions in the near term. It may, however, help with standardized elements like formatting compliance checks, predicate device searches, and initial triage of submission completeness.

MDUFA VI outcomes. The next user fee agreement will set the framework for FDA device review resources and performance expectations through 2032. If MDUFA VI includes stronger staffing commitments and refined performance metrics, it could drive meaningful improvement. If negotiations stall or result in weakened commitments, the current operational strain could become the new baseline.

Political and budgetary environment. The workforce reductions occurred within a broader context of federal spending review and political pressure on agency operations. Future budget cycles could bring additional cuts, restoration of lost positions, or a maintenance of the status quo. Companies should plan for continued uncertainty rather than assuming a return to pre-2024 staffing levels.

Key Takeaways

1. The FDA has lost 21% of its workforce and CDRH has lost 22% since September 2024. This is not a temporary dip -- it represents a fundamental shift in agency capacity that device manufacturers must account for in their regulatory planning.

2. Statutory review clocks are being met, but the operational environment around those clocks has degraded. Slower correspondence, delayed meetings, reviewer churn, and reduced policy output are all documented realities.

3. Small companies and startups are disproportionately affected. Cash constraints, limited parallel strategy options, and reduced ability to absorb timeline shifts make the current environment existentially threatening for some early-stage device companies.

4. AI/ML and novel technology reviews face the greatest risk. The specialist reviewer pool for AI/ML has been approximately halved, and rebuilding this expertise takes years, not months.

5. Pre-Submissions are more valuable than ever. Investing in thorough Pre-Submission packages -- with focused questions, concrete proposals, and early alignment on regulatory pathway -- is the single most effective strategy for de-risking your formal submission in the current environment.

6. Build buffer time into every timeline. Add 3-6 months to your expected 510(k) clearance timeline, 6-12 months for De Novo and PMA, and budget for the possibility that reviewer reassignment could add additional delays.

7. Pursue parallel regulatory strategies. Do not rely solely on the FDA timeline. Concurrent engagement with EU, UK, and other regulatory authorities provides market access alternatives and reduces the business impact of FDA delays.

8. The situation is dynamic. MDUFA VI negotiations, staffing recovery efforts, and the political environment will all shape FDA review operations over the next 12-18 months. Monitor developments closely and adjust your strategy accordingly.

The regulatory landscape has changed. The companies that adapt their planning assumptions, invest in submission quality, and maintain regulatory optionality will navigate this period successfully. Those that assume the FDA review process operates as it did in 2023 will face costly surprises.